To support the implementation of the new recommendations for the use of Lutényl, Lotéran and their generics with regard to the risk of meningioma, an information system, drawn up in connection with the committee made up of doctors and associative actors, is in preparation. Inspired by the communication tools implemented in 2019 to significantly reduce the use of another progestin medication associated with an over-risk of meningioma (Androcur and its generics) The information device will initially articulate on 2 tools:

• An information document to be given to each patient to start processing or pursuing it . This will specify what a meningioma is and report the level of risk according to the treatment taken. It will alert clinical signs likely to be associated with the presence of meningioma and will specify the conduct to be taken for each situation (re -evaluations at least once a year of the relevance of the processing, conditions for carrying out brain imaging, etc.).

• An annual information certificate to be completed by the patient and her doctor in order to promote exchange during consultation and guarantee the information of women both on the benefit / risk ratio of these drugs and on the methods of imaging by imagery in the event of processing. This certificate of information will be to be presented in pharmacies to obtain the processing, according to conditions which remain to be specified.

These documents will be available during spring.

In connection with the CNAM we study the possibility of sending an individual letter to the doctors who prescribed Lotényl or Lotéran and their generics to invite them to regain contact with the patients concerned in order to re-evaluate the merits of their treatment. In parallel, patients would also receive a personal letter inviting them to consult their doctor.

All of these tools will help limit the use of these drugs to situations only for which their prescription is justified.